Workflow
Bei Jing Shang Bao
icon
Search documents
国家医保局:对精神类定点医疗机构进行集体约谈
Bei Jing Shang Bao· 2026-02-04 10:00
同时,《通知》强调,国家医保局今年将重点对精神类定点医疗机构开展专项飞检,对违法违规使用医 保基金和自查自纠不到位的精神类定点医疗机构,将依法依规从重处理处罚,情节严重的移送公安机 关。 《通知》要求,各省级医保部门要组织本辖区内所有精神类定点医疗机构从即日起全面开展自查自纠, 重点聚焦但不限于诱导住院、虚假住院、虚构病情、虚构诊疗、伪造文书、违规收费等违法违规使用医 保基金行为,压实机构主体责任和机构主要负责人管理责任。各精神类定点医疗机构应于3月15日前完 成自查自纠,提交书面报告,完成涉及违法违规使用医保基金退款。各省级医保部门要于3月底前将自 查自纠情况报国家医保局。 北京商报讯(记者 王寅浩 宋雨盈)2月4日,国家医保局印发《关于对精神疾病类医保定点医疗机构开 展集体约谈的通知》(以下简称《通知》)。《通知》指出,为进一步加强精神疾病类医保定点医疗机 构(含综合医院精神科,以下简称精神类定点医疗机构)管理,严厉打击违法违规使用医保基金乱象, 各省级医保部门要于本周日前组织对辖区内所有精神类定点医疗机构主要负责人进行集体约谈,宣讲医 疗保障相关法律法规和监管政策。同时,以近期有关媒体曝光的湖北省襄阳市 ...
派林生物人凝血因子IX药品注册上市许可获受理
Bei Jing Shang Bao· 2026-02-04 09:40
Core Viewpoint - Palin Biopharma (000403) announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., received the approval notice for the marketing registration of human coagulation factor IX from the National Medical Products Administration [1] Group 1 - The approved drug, human coagulation factor IX, is indicated for the treatment of patients with congenital factor IX deficiency, specifically those with hemophilia B, or patients with low levels of factor IX due to other reasons [1] - The drug is expected to significantly increase the levels of human coagulation factor IX in the blood, thereby achieving the goal of preventing and treating bleeding [1]
康恩贝TFA003片临床试验获批
Bei Jing Shang Bao· 2026-02-04 09:40
Core Viewpoint - Kang En Bei (600572) has received approval from the National Medical Products Administration for clinical trials of TFA003, a drug aimed at treating diabetic kidney disease [1] Group 1: Company Developments - Kang En Bei's wholly-owned subsidiary, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., has been granted a Clinical Trial Approval Notice for TFA003 [1] - The drug has shown significant efficacy in improving renal function indicators in both urine and blood, as well as enhancing glomerular filtration and tubular reabsorption functions in animal studies [1] Group 2: Drug Potential - TFA003 demonstrates potential as a new drug for diabetic kidney disease, based on its pharmacological and pharmacokinetic results from preclinical studies [1] - The drug's ability to improve renal pathological morphology further supports its development as a treatment option for diabetic nephropathy [1]
四大渠道协同发力,兔宝宝2026重构家居产业价值生态
Bei Jing Shang Bao· 2026-02-04 09:13
Core Insights - The 2026 operational seminar of Rabbit Baby Decoration Materials was held in Deqing, Zhejiang, focusing on the theme "Rabbit Baby Makes Home Better" and outlining a development blueprint for "full-chain collaboration and high-quality growth" to address challenges in the home furnishing industry [1][12] Group 1: Strategic Focus - The company proposed three strategic pillars: "precise strategic reach, effective experience replication, and channel collaborative growth" to enhance its market position amid industry challenges [1] - The "customization+" channel strategy is central to Rabbit Baby's retail growth, emphasizing deep customization and broad channel support to optimize store operations and enhance profitability [2][4] Group 2: Channel Development - In the furniture factory channel, Rabbit Baby aims to transition from "material supply" to "integrated solutions," focusing on refined management and a differentiated product matrix to strengthen existing partnerships [5] - The home decoration channel is identified as a second growth curve, with a strategy centered on "deep collaboration" to meet the demand for systematic cooperation from construction enterprises [6][9] Group 3: Industry Positioning - The company is advancing towards becoming a "standard co-builder" in the construction channel, promoting green material applications and focusing on value competition rather than price competition [7][12] - Rabbit Baby emphasizes the importance of "full-channel collaboration" and high-value product innovation to upgrade its brand value system, aiming to transform into a one-stop home solution service provider [8][10]
黑龙江省金融控股集团有限公司原党委书记、董事长于宏严重违纪违法被开除党籍
Bei Jing Shang Bao· 2026-02-04 09:13
北京商报讯(记者 刘四红)2月4日,据黑龙江省纪委监委官网,日前,经黑龙江省委批准,黑龙江省 纪委监委对黑龙江省金融控股集团有限公司原党委书记、董事长于宏严重违纪违法问题进行了立案审查 调查。 经查,于宏丧失理想信念,背弃初心使命,罔顾中央八项规定精神,接受可能影响公正执行公务的宴 请;组织原则缺失,在职工录用、干部调转等工作中为他人谋取利益并收受钱款;廉洁底线失守,违规 收受礼金、消费卡,违规借用管理和服务对象钱款,违规从事营利活动;擅权妄为,干预和插手市场经 济活动;违反国家法律法规,非法持用伪造证件;将党和人民赋予的公权力异化为谋取私利的工具,为 他人在职工录用、干部调整、资金拨付、项目立项等方面谋取利益,并非法收受巨额财物。 于宏严重违反党的组织纪律、廉洁纪律和工作纪律,构成严重职务违法并涉嫌受贿犯罪,且在党的十八 大后不收敛、不收手,性质严重,影响恶劣,应予严肃处理。依据《中国共产党纪律处分条例》《中华 人民共和国监察法》《中华人民共和国公职人员政务处分法》等有关规定,经省纪委常委会会议研究并 报省委批准,决定给予于宏开除党籍处分;按规定取消其享受的待遇;收缴其违纪违法所得;将其涉嫌 犯罪问题移送检 ...
15只白酒股上涨 贵州茅台1525元/股收盘
Bei Jing Shang Bao· 2026-02-04 09:09
从个股来看,贵州茅台收盘价达1525.00元/股,上涨3.40%;五粮液收盘价达108.52元/股,上涨1.16%; 山西汾酒收盘价180.58元/股,上涨3.57%;泸州老窖收盘价达126.30元/股,上涨3.27%;洋河股份收盘 价达55.61元/股,上涨0.72%。 北京商报讯(记者刘一博冯若男)2月4日尾盘,沪指4102.20点上涨0.85%。白酒板块以2312.26点收盘上涨 0.90%,其中15只白酒股上涨,贵州茅台1525元/股收盘。 天风证券在其研报中指出,行业整体基本面回暖还需要外部宏观需求复苏的配合。但是在目前股市背景 下,股价有可能领先于基本面见底。天风证券认为。目前对板块或可以乐观一些。目前板块或处于基本 面出清的最后阶段,茅台批价企稳是边际改善的积极信号,板块估值修复或领先于业绩修复。 ...
北京拟立规管理帐篷露营地:夜间住宿应登记注册
Bei Jing Shang Bao· 2026-02-04 09:06
新规还提到,提供夜间住宿服务的帐篷露营地,应24小时专人值守并安装使用公安机关的信息采集系 统,录入经营单位及其从业人员基本信息,建立住宿登记制度,采集夜间住宿人员信息并上传。 北京商报讯(记者 关子辰 牛清妍)2月4日,记者从北京市文化和旅游局官网获悉,北京市文化和旅游 局会同相关部门起草《北京市帐篷露营地管理办法(征求意见稿)》,现向社会公开征求意见。新规指 出,帐篷露营地经营主体应规范登记注册,涉及夜间住宿、食品经营、举办国际体育赛事、高危险性赛 事和大型群众性活动等应依法依规办理。 ...
大北农实控人、董事长邵根伙因病逝世
Bei Jing Shang Bao· 2026-02-04 08:34
大北农表示,邵根伙逝世后,公司现任董事人数由9人减少至8人,不会导致公司董事会成员低于法定最 低人数。根据《公司章程》的规定,由公司副董事长张立忠代行董事长职责,直至公司董事会选举新任 董事长为止。目前,公司董事会、高级管理人员正常履职,公司各项经营业务正常开展。 据了解,邵根伙1965年生,中国农业大学农学博士。曾任教于北京农学院。1994年10月创建大北农。 北京商报讯(记者 马换换 李佳雪)2月4日,大北农(002385)披露公告称,公司实际控制人、董事长 邵根伙于2026年2月3日因病逝世,享年60岁。 ...
中信银行:拟以自有资金向中信金租增资20亿元
Bei Jing Shang Bao· 2026-02-04 08:34
中信银行披露的数据显示,截至2025年9月30日,中信金租资产总额1129.28亿元,负债总额996.71亿 元,净资产132.58亿元,资产负债率88.26%;2025年1—9月实现营业净收入16.64亿元,净利润11.84亿 元(以上数据未经审计)。 北京商报讯(记者 宋亦桐)2月4日,中信银行发布公告指出,拟使用自有资金向全资子公司中信金融 租赁有限公司(以下简称"中信金租")现金增资人民币20亿元(以下简称"本次增资")。本次增资已经 中信银行第七届董事会第二十一次会议审议通过,无需提交该行股东会审议。 据悉,本次增资完成后,中信金租注册资本将由100亿元增加至120亿元,中信银行仍持有中信金租 100%股权。 ...
2025年12月我国汽车整车出口同比增长73.2%
Bei Jing Shang Bao· 2026-02-04 08:27
Core Insights - The core viewpoint of the article highlights significant growth in China's automobile exports, both in volume and value, indicating a robust performance in the automotive industry [1] Group 1: Export Volume - In December 2025, the export volume of complete automobiles reached 994,000 units, representing a month-on-month increase of 21.4% and a year-on-year increase of 73.2% [1] - For the entire year of 2025, the total export volume of complete automobiles was 8.324 million units, showing a year-on-year growth of 29.9% [1] Group 2: Export Value - The export value in December 2025 amounted to $17.14 billion, with a month-on-month increase of 23.6% and a year-on-year increase of 71.7% [1] - The total export value for the year 2025 reached $142.46 billion, reflecting a year-on-year growth of 21.4% [1]